8-K: Health In Tech Reports Q1 2026 Results, Reiterates Annual Guidance

Health In Tech announced its first quarter 2026 financial results, showing a 9.4% revenue increase to $8.8 million, while reiterating its full-year revenue guidance of $45 million to $50 million.

Summary

• Health In Tech reported first quarter 2026 revenue of $8.8 million, a 9.4% increase compared to $8.0 million in the first quarter of 2025.
• The company's platform placed plan value reached $82.0 million.
• Adjusted EBITDA was $(1.3) million, a decrease from $1.2 million in Q1 2025, attributed to increased sales and marketing expenses.
• Net loss for the quarter was $1.6 million, or $(0.03) per diluted share, compared to a net income of $0.5 million, or $0.01 per diluted share, in Q1 2025.
• The number of distribution partners grew by 29.5% to 896 as of March 31, 2026.
• Contracted revenue for the remaining three quarters of 2026 is $22.9 million.
• Cash and cash equivalents increased to $10.3 million from $7.6 million year-over-year.
• The company reiterated its 2026 annual revenue guidance of $45 million to $50 million, representing 35% to 50% year-over-year growth.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with revenue growth and strong partner expansion offset by a net loss and increased operating expenses due to strategic investments.

Positives

• Revenue increased by 9.4% to $8.8 million in Q1 2026 compared to $8.0 million in Q1 2025.
• Distribution partners increased by 29.5% to 896 as of March 31, 2026.
• Cash and cash equivalents grew to $10.3 million as of March 31, 2026, up from $7.6 million in the prior year.
• Working capital increased to $15.0 million from $8.8 million year-over-year.
• The company reiterated its full-year 2026 revenue guidance of $45 million to $50 million, indicating expected growth of 35% to 50%.

Negatives

• Adjusted EBITDA turned negative at $(1.3) million in Q1 2026, compared to a positive $1.2 million in Q1 2025, due to higher sales and marketing expenses.
• The company reported a net loss of $1.6 million in Q1 2026, a reversal from a net income of $0.5 million in Q1 2025.
• Net loss per diluted share was $(0.03) in Q1 2026, compared to $0.01 per diluted share in Q1 2025.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors beyond the company's control.
• The company's revenue outlook is subject to management's current expectations and assumptions, including continued strong demand and successful deployment of new features.
• Risks and uncertainties are detailed in the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Health In Tech reiterated its 2026 annual revenue guidance to be between $45 million and $50 million, representing year-over-year growth of approximately 35% to 50%. The company expects continued growth driven by expanding engagement across its distribution network and the full deployment of new features launched in January 2026. New capabilities can be developed and deployed within one to two quarters due to the AI-driven platform.

Management Comments

• "In the first quarter of 2026, we continued to execute on strategic priorities to scale our innovative AI-powered self-funded health insurance marketplace and drive revenue growth."
• "In March, we successfully completed a private investment in public equity financing, which provided the Company with approximately $7 million in gross proceeds."
• "We intend to allocate a portion of these proceeds to growth initiatives, including expanding our sales team, broadening our marketing activities, delivering new marketplace offerings, and enhancing the technology architecture and data analytics that underpin our disruptive platform."
• "We intend for 2026 to be a year of investing for growth and launching new solutions to further penetrate the vast U.S. self-funded health insurance market."
• "Our recently rolled out suite of more than 100 pre-configured, customized stop-loss plans as well as our new three-year rate stabilization program are poised to deliver meaningful revenue beginning in the second half of the year."

Industry Context

StockSavvy.ai notes that Health In Tech's focus on an AI-enabled InsurTech platform for self-funded health insurance aligns with broader industry trends towards digitalization and automation in insurance. The company's ability to deploy new features rapidly (1-2 quarters) contrasts with traditional insurance product cycles (1-2 years), suggesting a competitive advantage in adapting to market demands.

Comparison to Industry Standards

• The company's development cycle for new features, estimated at 1-2 quarters, is significantly faster than the traditional insurance industry's typical 1-2 year implementation period for new products and services.
• Health In Tech's AI-driven platform aims to streamline underwriting, sales, and service processes, which is a key area of focus for innovation across the InsurTech sector.

Stakeholder Impact

• Shareholders: The company's strategic investments in growth may lead to future returns, but the current net loss and negative Adjusted EBITDA could be a concern in the short term. The PIPE financing dilutes existing shareholders but provides capital for expansion.
• Employees: Investments in sales, marketing, and technology may lead to job creation and growth opportunities within the company.
• Customers (Employers/Brokers/TPAs/Carriers): The company's platform enhancements and new offerings are designed to provide more efficient and cost-effective solutions for the self-funded health insurance market.

Next Steps

• Allocate proceeds from the recent PIPE financing to growth initiatives.
• Expand the sales team and broaden marketing activities.
• Deliver new marketplace offerings and enhance technology architecture and data analytics.
• Increase the number of brokers, agencies, third-party administrators, and carriers utilizing the ecosystem.
• Launch new solutions to penetrate the U.S. self-funded health insurance market.
• Deliver meaningful revenue from the new suite of stop-loss plans and three-year rate stabilization program starting in the second half of the year.
• Develop and launch a data-driven offering integrating physiological and claims data.

Key Dates

Recommendation

The company shows promising revenue growth and strategic expansion, but the shift to a net loss and negative Adjusted EBITDA, despite being attributed to growth investments, warrants a cautious 'hold' until profitability improves and the impact of new initiatives becomes clearer.

Keywords

Health In Tech, InsurTech, AI-enabled platform, Self-funded health insurance, Q1 2026 results, Revenue guidance, Adjusted EBITDA, Nasdaq: HIT